NHS may not cover high-cost Alzheimer's drug donanemab due to cost and limited benefits.

The UK's National Health Service (NHS) may not cover Eli Lilly's Alzheimer's drug, donanemab, due to its high cost, despite its potential to significantly slow cognitive decline. Following a similar decision on another drug, lecanemab, which was deemed too costly for its limited benefits, experts worry donanemab could face the same fate. Both drugs target amyloid buildup, but serious side effects have been reported. A decision on donanemab is expected soon.

October 22, 2024
126 Articles